The low number of CD4+ CD25+ regulatory T cells (Tregs), their anergic phenotype, and diverse antigen specificity present major challenges to harnessing this potent tolerogenic population to treat autoimmunity and transplant rejection. In this study, we describe a robust method to expand antigen-specific Tregs from autoimmune-prone nonobese diabetic mice. Purified CD4+ CD25+ Tregs were expanded up to 200-fold in less than 2 wk in vitro using a combination of anti-CD3, anti-CD28, and interleukin 2. The expanded Tregs express a classical cell surface phenotype and function both in vitro and in vivo to suppress effector T cell functions. Most significantly, small numbers of antigen-specific Tregs can reverse diabetes after disease onset, suggesting a novel approach to cellular immunotherapy for autoimmunity.
Skip Nav Destination
Article navigation
7 June 2004
Article|
June 07 2004
In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes
Qizhi Tang,
Qizhi Tang
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Search for other works by this author on:
Kammi J. Henriksen,
Kammi J. Henriksen
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Search for other works by this author on:
Mingying Bi,
Mingying Bi
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Search for other works by this author on:
Erik B. Finger,
Erik B. Finger
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Search for other works by this author on:
Greg Szot,
Greg Szot
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Search for other works by this author on:
Jianqin Ye,
Jianqin Ye
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Search for other works by this author on:
Emma L. Masteller,
Emma L. Masteller
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Search for other works by this author on:
Hugh McDevitt,
Hugh McDevitt
2Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305
Search for other works by this author on:
Mark Bonyhadi,
Mark Bonyhadi
3Xcyte Therapies, Inc., Seattle, WA 98104
Search for other works by this author on:
Jeffrey A. Bluestone
Jeffrey A. Bluestone
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Search for other works by this author on:
Qizhi Tang
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Kammi J. Henriksen
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Mingying Bi
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Erik B. Finger
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Greg Szot
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Jianqin Ye
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Emma L. Masteller
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Hugh McDevitt
2Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305
Mark Bonyhadi
3Xcyte Therapies, Inc., Seattle, WA 98104
Jeffrey A. Bluestone
1UCSF Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA 94143
Address correspondence to Jeffrey A. Bluestone, UCSF Diabetes Center, University of California San Francisco, Box 0540, 513 Parnassus Avenue, San Francisco, CA 94143. Phone: (415) 514-1683; Fax: (415) 564-5813; email: [email protected]
Abbreviations used in this paper: APC, allophycocyanin; CFSE, carboxyfluorescein diacetate succinimidyl ester; Ct, threshold cycle(s); GITR, glucocorticoid-induced TNF receptor; GAD, glutamic acid decarboxylase; NOD, nonobese diabetic; T1D, type 1 diabetes; Teff, T effector cell; Tg, transgenic; Treg, regulatory T cell.
Received:
January 22 2004
Accepted:
April 07 2004
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2004
J Exp Med (2004) 199 (11): 1455–1465.
Article history
Received:
January 22 2004
Accepted:
April 07 2004
Citation
Qizhi Tang, Kammi J. Henriksen, Mingying Bi, Erik B. Finger, Greg Szot, Jianqin Ye, Emma L. Masteller, Hugh McDevitt, Mark Bonyhadi, Jeffrey A. Bluestone; In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes . J Exp Med 7 June 2004; 199 (11): 1455–1465. doi: https://doi.org/10.1084/jem.20040139
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement